The 65-person Clinical Trials Team at the Winthrop P. Rockefeller Cancer Institute oversees approximately 260 active clinical studies, averaging 500 participants across 12 cancer types annually.
Trials include Phase 1 interventional treatment trials, NCI cooperative group studies and multiple investigator initiated trials.
Investigators have access to a dedicated Phase 1 Infusion Center, disease specific nursing and clinical research coordinator teams and an administrative team made up of regulatory specialists and financial analysts.
In the last year, the team has doubled in size, adding new employees across all teams and an organizational structure consistent with NCI Designated cancer centers.
“We have more than doubled our industry sponsored portfolio while balancing our cooperative group and investigator initiated studies,” said Director Matt Kovak, M.S., CCRP.
“We’re planning for exponential growth. As we diversify and expand our portfolio, we will expand trials across the entire state of Arkansas. Our goal is to provide clinical trials to rural and underrepresented areas across the state.”
High enrolling studies
260 active clinical studies averaging 500 participants across 12 cancer
types annually.
NRG-GY006
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, or Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer. This trial, led by Heather Williams, M.D., compares any good or bad effects of adding Triapine to the usual cisplatin chemotherapy and radiation therapy, compared to using cisplatin chemotherapy and radiation therapy alone.
S1914
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC. This trial, led by Sanjay Maraboyina, M.D., compares overall survival in patients with inoperable non-small cell lung cancer with both radiation and atezolizumab versus radiation alone.
NRG HN006
Randomized Phase II/III
Trial of Sentinel Lymph Node Biopsy versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer. This trial, led by Emre Vural, M.D., looks at the effects of neck and shoulder function zand discomfort compared between sentinel lymph node biopsy or the usual surgery for this type of cancer.
LUNGMAP
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study). This study, led by Konstantinos Arnaoutakis, M.D., is being conducted to find out if targeted or immunotherapy treatment will have an effect on specific genes and proteins in the tumor.